NCT01669889
Completed
N/A
A Multi-center, Non-drug Study to Explore the Relationship Between Exploratory Biomarkers and Functional Dimensions in Individuals With Autistic Disorder or Asperger's Syndrome.
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Healthy Volunteer, Autistic Disorder, Asperger's Syndrome
- Sponsor
- Hoffmann-La Roche
- Enrollment
- 38
- Primary Endpoint
- Cognition assessment ratings
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
This multi-center, non-drug study will explore the relationship between exploratory biomarkers and functional dimensions in male adult individuals with Autistic Disorder or Asperger's Syndrome and healthy volunteer controls. Subjects will undergo a number of assessments on study visit Day 1.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Individuals with Autistic Disorder or Asperger's Syndrome:
- •Male adults, 18 to 45 years of age inclusive
- •Diagnosis of Autistic Disorder or Asperger's Syndrome as defined by DSM-IV
- •Body mass index (BMI) 18 to 35 kg/m2
- •Availability of a reliable caregiver, able and willing to provide information regarding the individual's behavior and symptoms
- •Healthy controls:
- •Healthy male adults, 18 to 45 years of age inclusive
- •Body mass index (BMI) 18 to 30 kg/m2
Exclusion Criteria
- •General exclusion criteria:
- •Positive test for drugs of abuse or alcohol
- •Confirmed systolic blood pressure \>140 or \<90 mmHg, and diastolic blood pressure \>90 or \<50 mmHg
- •Resting pulse rate \>100 or \<40 beats per minute
- •Alcohol and/or substance abuse/dependence during the last 12 months
- •Concomitant disease or condition that could interfere with, or treatment of which might interfere with, the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study
- •Additionally for individuals with Autistic Disorder or Asperger's Syndrome:
- •History of epilepsy/seizure disorder (except simple febrile seizures)
- •Significant disruptive, aggressive or self-injurious, or sexually inappropriate behavior during the last 3 months that in the opinion of the investigator might interfere with the conduct of the study
- •Additionally for healthy controls:
Outcomes
Primary Outcomes
Cognition assessment ratings
Time Frame: approximately 5 months
Behavior assessment ratings
Time Frame: approximately 5 months
Similar Trials
Completed
N/A
Exploratory study to investigate biomarkers associated with pathogenesis of infantile hemangioma.Infantile hemangiomaJPRN-UMIN000038574Wakayama Medical University45
Completed
N/A
Asthma Biomarker StudyAsthmaNCT02392481Boehringer Ingelheim69
Not Yet Recruiting
N/A
Exploratory research of biomarkers for investigational drugs using tear fluid samplesJPRN-UMIN000049186Santen Pharmaceutical Co. Ltd.29
Terminated
N/A
An Observational Study of MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in First-Line in Patients With Diffuse Large B-Cell LymphomaDiffuse Large B-Cell LymphomaNCT01724294Hoffmann-La Roche113
Completed
N/A
Quantify the Benefits of Biomarkers in Routine Patient Care in Kidney Transplant RecipientsRenal TransplantationNCT04774575Assistance Publique - Hôpitaux de Paris300